Telomerase Activator and Retinal Amyloid

Completed · Not applicable · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and has a predictive value in Alzheimer's disease. Telomere attrition accounts for cellular aging and is felt to have a pivotal role in Alzheimer's disease. The investigators plan to screen individuals to select those having retinal amyloid then evaluate an oral telomerase activator to determine if its use can alter the RAI over time compared to placebo.

Key facts

Study ID

NCT02530255

Run by

Chippewa Valley Eye Clinic

People needed

48

Starts

2016-12-01

Expected to finish

2018-12-31

Last updated by the study team

2019-07-05

Who can join

Age: 50 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• qualifying retinal amyloid index (RAI) number as determined at screening
• Must be able to swallow capsule

You may not qualify if…

• Cancer treatment within 5 years (except non-melanoma skin cancer)
• Must be able to swallow capsule

Where it is running

• Chippewa Valley Eye Clinic — Eau Claire, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.